Radiopeptide Imaging and Therapy in the United States

Graham, Michael M.; Menda, Yusuf

doi:10.2967/jnumed.110.085746

Cited by 69 publications

(37 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiolabelled receptor-binding peptides have become important radiopharmaceuticals for diagnosis and therapy in tumor [57][58][59][60][61] .…”

Section: Radiolabeled Peptides For Pc Imagingmentioning

confidence: 99%

Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

Xu¹

2016

WJGO

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a major health problem. Conventional imaging modalities show limited accuracy for reliable assessment of the tumor. Recent researches suggest that molecular imaging techniques with tracers provide more biologically relevant information and are benefit for the diagnosis of the cancer. In addition, radiopharmaceuticals also play more important roles in treatment of the disease. This review summaries the advancement of the radiolabeled compounds in the theranostics of PC.

show abstract

“…Radiolabelled receptor-binding peptides have become important radiopharmaceuticals for diagnosis and therapy in tumor [57][58][59][60][61] .…”

Section: Radiolabeled Peptides For Pc Imagingmentioning

confidence: 99%

Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

Xu¹

2016

WJGO

View full text Add to dashboard Cite

show abstract

“…One challenge that should be considered by stakeholders is to identity ways to propel existing data on TRT forward more quickly in support of U.S. approvals. Another challenge is to directly address the various logistic problems cited in the workshop: limited access to TRT for patients and providers, perceived high cost, turf issues, patient perceptions and fears, and the need for multidisciplinary teams supported by strong TRT education efforts (123)(124)(125)(126)(127)(128)(129)(130)(131)(132).…”

Section: Workhop Summarymentioning

confidence: 99%

Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging

et al. 2014

View full text Add to dashboard Cite

The growing interest in targeted radionuclide therapy (TRT) for a broad range of applications is shared by a diverse group of medical professionals, including but not limited to physicians and basic scientists in several fields, as well as members of industry, regulatory bodies, and patients. However, no organizational structure is available to regularly bring these stakeholders together to discuss the latest findings and the most productive strategies to ensure that the potential benefits of TRT are realized.

show abstract

“…Due to many favorable properties for molecular imaging, such as advantageous pharmacokinetics and specific tumor targeting characteristics, including the overexpression of peptide receptors on the tumor cells, radiolabeled peptides have an important impact not only in PET imaging of cancer, but also in targeted radionuclide therapy [10]. Peptide-based radiopharmaceuticals have been successfully employed for imaging of somatostatin (SST) and bombesin or cholecystokinin/gastrin receptor overexpressing tumors, all common human cancers [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application

et al. 2018

View full text Add to dashboard Cite

Radiolabeled amino acids, their derivatives and peptides have a broad scope of application and can be used as receptor ligands, as well as enzyme substrates for many different diseases as radiopharmaceutical tracers. Over the past few decades, the application of molecular imaging techniques such as positron emission tomography (PET) has gained considerable importance and significance in diagnosis in today's advanced health care. Next to that, the availability of cyclotrons and state-of-the-art radiochemistry facilities has progressed the production of imaging agents enabling the preparation of many versatile PET radiotracers. Due to many favorable characteristics of radiolabeled amino acids and peptides, they can be used for tumor staging and monitoring the progress of therapy success, while aromatic amino acids can be employed as PET tracer to study neurological disorders. This review provides a comprehensive overview of radiosynthetic and enzymatic approaches towards carbon-11 amino acids, their analogues and peptides, with focus on stereoselective reactions, and reflects upon their clinical application.

show abstract

Radiopeptide Imaging and Therapy in the United States

Cited by 69 publications

References 50 publications

Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging

From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application

Contact Info

Product

Resources

About